Journal editorial - The emerging story of Myval transcatheter heart valve: lessons from the LANDMARK trial
ESC Cardio Talk
00:00
Patient-prosthesis mismatch differences
Paolo reviews PPM rates: Myval ~11%, Sapien >22%, Evolut 6%, and discusses surgical-derived thresholds.
Play episode from 01:59
Transcript
